[go: up one dir, main page]

MX2018007520A - Composicion farmaceutica que comprende un anticuerpo receptor de linfopoyetina estromal timica antihumano. - Google Patents

Composicion farmaceutica que comprende un anticuerpo receptor de linfopoyetina estromal timica antihumano.

Info

Publication number
MX2018007520A
MX2018007520A MX2018007520A MX2018007520A MX2018007520A MX 2018007520 A MX2018007520 A MX 2018007520A MX 2018007520 A MX2018007520 A MX 2018007520A MX 2018007520 A MX2018007520 A MX 2018007520A MX 2018007520 A MX2018007520 A MX 2018007520A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
receptor antibody
human tslp
tslp receptor
composition containing
Prior art date
Application number
MX2018007520A
Other languages
English (en)
Inventor
Ikeda Megumi
Chikushi Akinori
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2018007520A publication Critical patent/MX2018007520A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporciona una composición farmacéutica estable, que comprende un anticuerpo receptor de TSLP antihumano, capaz de inhibir la generación de sustancias químicamente modificadas, tal como formas desaminadas y formas oxidadas, o degradantes o multímeros. La composición farmacéutica comprende un anticuerpo receptor de TSLP antihumano, una solución amortiguadora farmacéuticamente aceptable, arginina o una sal farmacéuticamente aceptable del mismo, y un tensoactivo.
MX2018007520A 2015-12-18 2016-12-16 Composicion farmaceutica que comprende un anticuerpo receptor de linfopoyetina estromal timica antihumano. MX2018007520A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015246826 2015-12-18
PCT/JP2016/087480 WO2017104778A1 (ja) 2015-12-18 2016-12-16 抗ヒトｔｓｌｐ受容体抗体含有医薬組成物

Publications (1)

Publication Number Publication Date
MX2018007520A true MX2018007520A (es) 2018-08-01

Family

ID=59056678

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018007520A MX2018007520A (es) 2015-12-18 2016-12-16 Composicion farmaceutica que comprende un anticuerpo receptor de linfopoyetina estromal timica antihumano.

Country Status (10)

Country Link
US (3) US10994011B2 (es)
EP (2) EP3391904B1 (es)
JP (3) JP6897570B2 (es)
KR (1) KR102800281B1 (es)
CN (1) CN108430507B (es)
MX (1) MX2018007520A (es)
PH (1) PH12018501243B1 (es)
SG (2) SG11201805123XA (es)
TW (2) TWI836745B (es)
WO (1) WO2017104778A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI836745B (zh) 2015-12-18 2024-03-21 美商上游生物公司 含有抗人類ｔｓｌｐ受體抗體之醫藥組成物
EP3558363A1 (en) 2016-12-21 2019-10-30 Amgen Inc. Anti-tnf alpha antibody formulations
WO2020075746A1 (ja) * 2018-10-10 2020-04-16 アステラス製薬株式会社 標識部－抗ヒト抗体Ｆａｂフラグメント複合体を含む医薬組成物
WO2021038532A1 (en) * 2019-08-30 2021-03-04 Kashiv Biosciences, Llc Novel formulation of highly concentrated pharmacologically active antibody
AU2021219839A1 (en) * 2020-02-13 2022-08-25 Amgen Inc. Formulations of human anti-TSLP antibodies and methods of treating inflammatory disease
WO2024098180A1 (en) * 2022-11-07 2024-05-16 Wuxi Biologics (Hong Kong) Limited Pharmaceutical compositions comprising anti-human tslp receptor antibodies and methods of using the same
TW202235437A (zh) * 2021-03-03 2022-09-16 大陸商正大天晴藥業集團股份有限公司 含抗tslp抗體的藥物組合物
CN116251181B (zh) * 2021-12-02 2023-09-22 北京东方百泰生物科技股份有限公司 一种抗tslp单克隆抗体的注射制剂
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
JP2025538151A (ja) * 2022-11-07 2025-11-26 アップストリーム バイオ インコーポレイテッド 抗ヒトｔｓｌｐ受容体抗体を含む医薬組成物及びその使用方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
ES2317917T3 (es) 2000-06-28 2009-05-01 Amgen Inc. Moleculas de receptor de linfopoyetina estromal timica y sus usos de las mismas.
PT1478394E (pt) * 2002-02-27 2008-10-08 Immunex Corp Composição estabilizada compreendendo tnfr - fc e arginina
CA2519408C (en) 2003-04-04 2011-01-18 Genentech, Inc. High concentration antibody and protein formulations
JP2007522157A (ja) * 2004-02-12 2007-08-09 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 抗ｅｇｆｒ抗体の高濃縮液体製剤
US20050249712A1 (en) 2004-03-23 2005-11-10 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for use of TSLP and agonists and antagonists thereof
KR101383472B1 (ko) 2006-01-13 2014-04-08 아이알엠 엘엘씨 알레르기 질병 치료를 위한 흉선 간질 림포포이에틴수용체에 대한 항체
NZ571757A (en) * 2006-04-21 2012-01-12 Novartis Ag Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer
US7763070B2 (en) 2006-07-25 2010-07-27 C&C Vision International Limited “W” accommodating intraocular lens
EP2170957A1 (en) 2007-06-20 2010-04-07 Irm, Llc Methods and compositions for treating allergic diseases
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
CA2713935C (en) 2008-02-07 2016-11-01 Schering Corporation Engineered anti-tslpr antibodies
SI2331090T1 (en) 2008-09-19 2018-04-30 Pfizer Inc. Stable liquid antibody formulation
RU2565809C2 (ru) 2009-03-19 2015-10-20 Чугаи Сейяку Кабусики Кайся Фармацевтический состав, содержащий молекулы антител с улучшенными свойствами
AR082163A1 (es) 2010-07-15 2012-11-14 Hoffmann La Roche Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos
US20120020960A1 (en) 2010-07-26 2012-01-26 Baylor Research Institute Thymic Stromal Lymphopoietin (TSLP) and OX40 Ligand in Cancer
CN103501825B (zh) 2011-05-02 2017-03-15 免疫医疗公司 用于小体积施用的同种异型选择的抗体的超滤浓缩
US9216219B2 (en) * 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
WO2014031718A1 (en) 2012-08-23 2014-02-27 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
EP2727602A1 (en) 2012-10-31 2014-05-07 Takeda GmbH Method for preparation of a high concentration liquid formulation of an antibody
UY35460A (es) 2013-03-15 2014-10-31 Bayer Healthcare Llc Formulaciones de anticuerpos anti-receptor de prolactina
LT3031913T (lt) 2013-08-09 2019-05-27 Astellas Pharma Inc. Naujas antikūnas, atpažįstantis žmogaus tslp receptorių
TWI836745B (zh) 2015-12-18 2024-03-21 美商上游生物公司 含有抗人類ｔｓｌｐ受體抗體之醫藥組成物
AU2018255955A1 (en) 2017-04-18 2019-12-05 Dr. Reddy's Laboratories Limited Stable liquid pharmaceutical composition
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
JP2021521171A (ja) 2018-04-10 2021-08-26 ドクター レディズ ラボラトリーズ リミテッド 治療用抗体の安定な製剤
WO2019198100A1 (en) 2018-04-10 2019-10-17 Dr. Reddy's Laboratories Limited Antibody formulation

Also Published As

Publication number Publication date
PH12018501243B1 (en) 2022-11-04
KR102800281B1 (ko) 2025-04-23
JPWO2017104778A1 (ja) 2018-10-04
RU2018126355A (ru) 2020-01-22
HK1255877A1 (zh) 2019-08-30
US11712472B2 (en) 2023-08-01
US20220023422A1 (en) 2022-01-27
RU2018126355A3 (es) 2020-03-10
EP3391904A1 (en) 2018-10-24
TW202310873A (zh) 2023-03-16
TWI787161B (zh) 2022-12-21
US10994011B2 (en) 2021-05-04
JP6897570B2 (ja) 2021-06-30
TW201733618A (zh) 2017-10-01
KR20180088906A (ko) 2018-08-07
CA3008779A1 (en) 2017-06-22
JP2021127348A (ja) 2021-09-02
SG10202012778YA (en) 2021-01-28
WO2017104778A1 (ja) 2017-06-22
PH12018501243A1 (en) 2019-01-28
JP7208302B2 (ja) 2023-01-18
SG11201805123XA (en) 2018-07-30
JP2023029500A (ja) 2023-03-03
US20230398213A1 (en) 2023-12-14
EP4506016A3 (en) 2025-06-04
EP3391904A4 (en) 2019-09-25
US20190111129A1 (en) 2019-04-18
US12447210B2 (en) 2025-10-21
CN108430507B (zh) 2022-08-02
TWI836745B (zh) 2024-03-21
CN108430507A (zh) 2018-08-21
EP4506016A2 (en) 2025-02-12
EP3391904B1 (en) 2024-12-04

Similar Documents

Publication Publication Date Title
MX2018007520A (es) Composicion farmaceutica que comprende un anticuerpo receptor de linfopoyetina estromal timica antihumano.
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
PH12018500034A1 (en) Bicyclic lactams and methods of use thereof
PH12020550703A1 (en) Sulfonamide compounds and use thereof
MX2018015280A (es) Conjugados de anticuerpo y farmaco anti-egfr.
PH12022553314A1 (en) Anti-egfr antibody drug conjugates
MX2021015102A (es) Inhibidores del receptor del factor estimulante de colonias 1 (csf-1r).
MX2018011139A (es) Acido acrilico y metodos para producir el mismo.
MX2021010471A (es) Anticuerpos y conjugados de anticuerpo y farmaco anti-egfr.
TW201613859A (en) Analogs of PRIDOPIDINE, their preparation and use
PH12015502031B1 (en) Tetrahydropyrrolothiazine compounds
TN2013000378A1 (en) Anti - sclerostin antibody crystals and formulations thereof
MX2018015284A (es) Conjugados de anticuerpo anti-egfr y fármaco.
MX2017004975A (es) Composiciones de anticuerpos anti-il-7r.
AU2017317563A8 (en) Detergent compositions comprising xanthan lyase variants I
ZA201703510B (en) Antibodies, uses & methods
MX2018000395A (es) Proteinas y composiciones inmunizantes que contienen proteinas de klebsiella y metodos de uso.
AU2015316010A8 (en) Crystalline forms of 6-( (6, 7-dimethoxyquinazolin-4-yl) oxy) -N,2-dimethylbenzofuran-3-carboxamide
MX2017000527A (es) Formulaciones de anticuerpos cristalinos.
UA117779C2 (uk) Піразини як модулятори gpr6
WO2016024289A3 (en) Novel salts of nilotinib and polymorphs thereof
MX2016017367A (es) Dioxido de zirconio, producto refractario, uso de dioxido de zirconio, procedimiento para la fabricacion de un producto refractario asi como un producto refractario fabricado mediante el mismo.
EA201790321A1 (ru) Эластомерные композиции, содержащие усниновую кислоту, и изделия, изготовленные из них или покрытые ими
TWD172799S (zh) 瓶子之部分
MA39877A (fr) Formes solides d'un composé pharmaceutiquement actif